Fabian Franco, MD
Geriatric Medicine · Warner Robins, GANPI 1649237207
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 158 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations.
Across 158 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$530
- Amgen$359
- Novo Nordisk$351
- Lilly USA, LLC$341
- Abbott$298
- Otsuka America Pharmaceutical, Inc.$176
- plus $910 from 25 others
What the payments were for
- Food & beverage$2,965100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $530 |
| Amgen | 22 | $359 |
| Novo Nordisk | 18 | $351 |
| Lilly USA, LLC | 21 | $341 |
| Abbott | 11 | $298 |
| Otsuka America Pharmaceutical, Inc. | 9 | $176 |
| AbbVie(2 entities) | 5 | $67 |
| Merck | 4 | $64 |
| Lundbeck LLC | 3 | $64 |
| Exact Sciences | 4 | $64 |
| Johnson & Johnson | 4 | $58 |
| Biogen | 3 | $56 |
| AstraZeneca | 4 | $55 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Esperion Therapeutics, Inc. | 3 | $44 |
| Paratek Pharmaceuticals, Inc. | 2 | $41 |
| Dexcom, Inc. | 2 | $38 |
| Inogen, Inc. | 2 | $38 |
| Medtronic(2 entities) | 2 | $34 |
| Eisai Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Boehringer Ingelheim | 2 | $29 |
| Seqirus USA Inc | 1 | $24 |
| Vertex | 1 | $24 |
| PBG Puerto Rico LLC | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$124
How this compares
$2,965 in reported general payments places this provider in the 85th percentile of 75 geriatric medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 215 | $219,560 |
| OzempicSemaglutide | 75 | $104,515 |
| FarxigaDapagliflozin Propanediol | 81 | $80,394 |
| JanuviaSitagliptin Phosphate | 72 | $64,513 |
| MounjaroTirzepatide | 46 | $61,357 |
| JardianceEmpagliflozin | 35 | $32,900 |
| XareltoRivaroxaban | 23 | $30,546 |
| TrulicityDulaglutide | 14 | $19,789 |
| LinzessLinaclotide | 19 | $18,999 |
| SynjardyEmpagliflozin/Metformin Hcl | 15 | $11,354 |
| Repatha SureclickEvolocumab | 19 | $10,972 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,989 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $7,967 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $6,436 |
| Atorvastatin Calcium | 607 | $5,798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $530 | $219,560215 claims |
| Novo NordiskOzempic | $351 | $104,51575 claims |
| AstraZenecaFarxiga, Symbicort | $55 | $86,82992 claims |
| Lilly USA, LLCMounjaro, Trulicity | $341 | $81,14660 claims |
| MerckJanuvia | $64 | $64,51372 claims |
| Boehringer IngelheimJardiance, Synjardy | $29 | $44,25450 claims |
| Johnson & JohnsonXarelto | $58 | $30,54623 claims |
| AbbVieLinzess, Synthroid | $67 | $20,63655 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 75 geriatric medicine providers in Georgia.
Other geriatric medicine in Warner Robins
- Rommer TayagWarner Robins$3K
- Joseph MiccaMarietta$130K
- Monica ParkerAtlanta$74K
- Daniel DinoSt Marys$13K
- Wayne MorrisAthens$12K
- Harry StrothersMacon$10K
- Scott MikellStatesboro$10K
- Theodore JohnsonAtlanta$6K
- Anitha KoduruEvans$6K
- Sudeshna NandiDuluth$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.